Startseite>>Peptides>>OVA Peptide 323-339

OVA Peptide 323-339

Katalog-Nr.GC34266

Das OVA-Peptid (323-339) stellt ein T- und B-Zell-Epitop von Ovalbumin (Ova) dar, das bei der Erzeugung und Entwicklung von unmittelbaren Überempfindlichkeitsreaktionen in BALB/c-MÄusen wichtig ist.

Products are for research use only. Not for human use. We do not sell to patients.

OVA Peptide 323-339 Chemische Struktur

Cas No.: 92915-79-2

Größe Preis Lagerbestand Menge
1mg
101,00 $
Auf Lager
5mg
405,00 $
Auf Lager
10mg
726,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment:

A20 B cell lines are loaded, or not, with different concentrations of OVA Peptide (323-339) overnight. Cells are then conjugated with purified mouse CD4+ T cells and incubated for 20 h. After the 20 h incubation period, supernatant is recovered and stored at -20°C. IFN-γ production is quantified in the supernatants by sandwich ELISA. 96-well plates are analyzed. T cells cultured for two to four days in the presence of 3 μg/mL of anti-CD3 antibody are used as positive control of T cell activation. B cells cultured for 48 h in the presence of 2.5 μg/mL of anti-CD40 antibody and 5 μg/mL of the F(ab’)2/F(ab) portion of an anti-mouse IgG antibody are used as positive control for B cell activation[1].

Animal experiment:

Mice[2] Fifty-one 8-week-old female BALB/c mice are randomly divided into three groups: OVA, OVA 323-339 and saline. They are intraperitoneally injected with 25 μg OVA or OVA Peptide (323-339) absorbed on 300 μg Alum or saline on days 0, 7, 14. On days 21-23, all groups are challenged intranasally with 20 μL of 1% OVA, 1% OVA Peptide (323-339) and saline, respectively. On days 0, 7, 14, mice are intraperitoneally injected with 25 μg OVA or OVA Peptide (323-339) absorbed on 300 μg Alum, or saline; on days 21-23, all groups are challenged intranasally with either 20 μL of 1% OVA, 1% OVA Peptide (323-339) or saline. On day 28, after killing, splenocytes are isolated and cultured under the stimulus of each allergen or medium.

References:

[1]. Fontinha D, et al. Murid Gammaherpesvirus Latency-Associated Protein M2 Promotes the Formation of Conjugates between Transformed B Lymphoma Cells and T Helper Cells. PLoS One. 2015 Nov 6;10(11):e0142540.
[2]. Sun LZ, et al. Comparison between ovalbumin and ovalbumin peptide 323-339 responses in allergic mice: humoral and cellular aspects. Scand J Immunol. 2010 May;71(5):329-35.

Background

OVA Peptide (323-339) represents a T and B cell epitope of Ovalbumin (Ova), which is important in the generation and development of immediate hypersensitivity responses in BALB/c mice.

When pulsed with 0.01 μM of OVA Peptide (323-339), M2-expressing B cells lead to an increase in the number of TH cells mobilizing calcium, compared to M2Y-expressing B cells. To assess if M2-expressing B cells are also able to promote stronger individual responses, we quantified the 405/530 ratio MFI of responding TH cells[1].

OVA Peptide (323-339) represents a T and B cell epitope of OVA, which is important in the generation and development of immediate hypersensitivity responses in BALB/c mice. Daily aerosolization of OVA Peptide (323-339) for 20 minutes over a period of 10 days has been as effective in the stimulation of a serum anti-OVA IgE antibody response as sensitization to native OVA by the same route. After sensitization to native OVA, the majority of the IgE anti-OVA response is directed against OVA Peptide (323-339). Evaluated by hematoxylin/eosin and major basic protein immunohistochemical stainings, OVA and OVA Peptide (323-339) induce similar lung inflammation. Interestingly, significant serum total IgE and OVA-specific IgE are observed in OVA mice when compared to saline control. OVA Peptide (323-339) mice show higher serum OVA-specific IgE, OVA Peptide (323-339)-specific IgE, IL-4 and lower IFN-γ similar to OVA mice. The proliferative response to OVA is found in cultured splenocytes of both OVA and OVA Peptide (323-339) mice, while the similar proliferative response to OVA Peptide (323-339) is only observed in the splenocytes of OVA Peptide (323-339)-sensitized and challenged mice. Although OVA Peptide (323-339) induces a Th2-like response in the mouse model as does OVA, OVA Peptide (323-339) has clearly limited immunogenic potency to activate OVA-sensitized and challenged mice splenocytes, unlike OVA[2].

[1]. Fontinha D, et al. Murid Gammaherpesvirus Latency-Associated Protein M2 Promotes the Formation of Conjugates between Transformed B Lymphoma Cells and T Helper Cells. PLoS One. 2015 Nov 6;10(11):e0142540. [2]. Sun LZ, et al. Comparison between ovalbumin and ovalbumin peptide 323-339 responses in allergic mice: humoral and cellular aspects. Scand J Immunol. 2010 May;71(5):329-35.

Chemical Properties

Cas No. 92915-79-2 SDF
Canonical SMILES Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg
Formula C74H120N26O25 M.Wt 1773.91
Löslichkeit Water : ≥ 50 mg/mL (28.19 mM) Storage -20°C, protect from light
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 0.5637 mL 2.8186 mL 5.6373 mL
5 mM 0.1127 mL 0.5637 mL 1.1275 mL
10 mM 0.0564 mL 0.2819 mL 0.5637 mL
  • Molaritätsrechner

  • Verdünnung-Rechner

Gewicht
=
Konzentration
x
Inhalt
x
MW*
 
 
 
**Bei der Herstellung von Stammlösungen ist immer das chargenspezifische Molekulargewicht von

Berechnen

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Bewertungen

Review for OVA Peptide 323-339

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for OVA Peptide 323-339

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.